Publications

Corrigendum to “Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial” [Eur. Eurol. 84(2) (2023) 156–163, (S0302283823027884), (10.1016/j.eururo.2023.04.024)]

Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin M, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Neil Reaume M, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA 2024 Sep 86 289-290

Performance deterioration of deep learning models after clinical deployment: a case study with auto-segmentation for definitive prostate cancer radiotherapy

Wang B, Dohopolski M, Bai T, Wu J, Hannan R, Desai N, Garant A, Yang D, Nguyen D, Lin MH, Timmerman R, Wang X, Jiang SB 2024 Jun 5

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial

Buyyounouski MK, Pugh SL, Chen RC, Mann MJ, Kudchadker RJ, Konski AA, Mian OY, Michalski JM, Vigneault E, Valicenti RK, Barkati M, Lawton CA, Potters L, Monitto DC, Kittel JA, Schroeder TM, Hannan R, Duncan CE, Rodgers JP, Feng F, Sandler HM 2024 May 10 584-591

Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology

Marvaso G, Jereczek-Fossa BA, Zaffaroni M, Vincini MG, Corrao G, Andratschke N, Balagamwala EH, Bedke J, Blanck O, Capitanio U, Correa RJ, De Meerleer G, Franzese C, Gaeta A, Gandini S, Garibaldi C, Gerszten PC, Gillessen S, Grubb WR, Guckenberger M, Hannan R, Jhaveri PM, Josipovic M, Kerkmeijer LG, Lehrer EJ, Lindskog M, Louie AV, Nguyen QN, Ost P, Palma DA, Procopio G, Rossi M, Staehler M, Tree AC, Tsang YM, Van As N, Zaorsky NG, Zilli T, Pasquier D, Siva S 2024 May 25 e193-e204

Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles

Yaman S, Ramachandramoorthy H, Iyer P, Chintapula U, Nguyen T, Sabnani M, Kotadia T, Ghaffari S, Pop LM, Hannan R, Weidanz JA, Nguyen KT 2024 Apr 34 422-435

Harnessing stereotactic precision in the fight against primary kidney cancer: time for a randomised trial?

Yang DX, Hannan R 2024 Mar 25 267-269

Stereotactic ablative radiotherapy for primary renal cell carcinoma

Yang DX, Kwon YS, Timmerman R, Hannan R 2024 Jan 44

Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: A Case-Based Radiosurgery Society Practice Guide

Barbour AB, Upadhyay R, Anderson AC, Kutuk T, Kumar R, Wang SJ, Psutka SP, Fekrmandi F, Skalina KA, Bruynzeel AM, Correa RJ, Dal Pra A, Biancia CD, Hannan R, Louie A, Singh AK, Swaminath A, Tang C, Teh BS, Zaorsky NG, Lo SS, Siva S 2024

Radiation-Induced Innate Neutrophil Response in Tumor Is Mediated by the CXCLs/CXCR2 Axis

Zhang F, Mulvaney O, Salcedo E, Manna S, Zhu JZ, Wang T, Ahn C, Pop LM, Hannan R 2023 Dec 15

Bony structure enhanced synthetic CT generation using Dixon sequences for pelvis MR-only radiotherapy

Liang X, Yen A, Bai T, Godley A, Shen C, Wu J, Meng B, Lin MH, Medin P, Yan Y, Owrangi M, Desai N, Hannan R, Garant A, Jiang S, Deng J 2023 Dec 50 7368-7382

Role of primary and metastasis-directed stereotactic radiation therapy for advanced renal cell carcinoma

Christensen M, Hannan R 2023 Nov 343-357

Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer

Hannan R, McLaughlin MF, Pop LM, Pedrosa I, Kapur P, Garant A, Ahn C, Christie A, Zhu J, Wang T, Robles L, Durakoglugil D, Woldu S, Margulis V, Gahan J, Brugarolas J, Timmerman R, Cadeddu J 2023 Sep 84 275-286

Life-threatening hemoptysis in patients with metastatic kidney cancer

Patel VM, Elias R, Asokan A, Sharma A, Christie A, Pedrosa I, Chiu H, Reznik S, Hannan R, Timmerman R, Brugarolas J 2023 Aug 21 497-506

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors

Mundra V, Yang Y, von Itzstein MS, Fattah F, Gonugunta AS, Hannan R, Pop LM, Zhang Y, Wang Y, Sheffield T, Xie Y, Dowell JE, Homsi J, Rashdan S, Park J, Li Q, Wakeland EK, Gerber DE 2023 Aug 34

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial

Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA 2023 Aug 84 156-163

Preliminary Evaluation of PTV Margins for Online Adaptive Radiation Therapy of the Prostatic Fossa

Morgan HE, Wang K, Yan Y, Desai N, Hannan R, Chambers E, Cai B, Lin MH, Sher DJ, Wang J, Wang AZ, Jiang S, Timmerman R, Park C“, Garant A 2023 Jul 13 e345-e353

Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers

Huynh MA, Tang C, Siva S, Berlin A, Hannan R, Warner A, Koontz B, De Meeleer G, Palma D, Ost P, Tran PT 2023 Feb 6 28-38

Tumor loss-of-function mutations in STK11/LKB1 induce cachexia

Iyengar P, Gandhi AY, Granados J, Guo T, Gupta A, Yu J, Llano EM, Zhang F, Gao A, Kandathil A, Williams D, Gao B, Girard L, Malladi V, Shelton JM, Evers BM, Hannan R, Ahn C, Minna JD, Infante RE 2023 8

Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer

Hannan R, Christensen M, Christie A, Garant A, Pedrosa I, Robles L, Mannala S, Wang C, Hammers H, Arafat W, Courtney K, Bowman IA, Sher D, Ahn C, Cole S, Choy H, Timmerman R, Brugarolas J 2022 Dec 5 695-703

The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma

Ali M, Mooi J, Lawrentschuk N, McKay RR, Hannan R, Lo SS, Hall WA, Siva S 2022 Dec 82 613-622

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)

Siva S, Ali M, Correa RJ, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A, McLaughlin M, Morgan SC, Cury FL, Teh BS, Mahadevan A, Kaplan ID, Chu W, Grubb W, Hannan R, Staehler M, Warner A, Louie AV 2022 Dec 23 1508-1516

Corrigendum to “The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma” [Eur Urol 2022] (European Urology, (S030228382202468X), (10.1016/j.eururo.2022.06.017))

Ali M, Mooi J, Lawrentschuk N, McKay RR, Hannan R, Lo SS, Hall WA, Siva S 2022 Nov 82 e152

The Emerging Role of Radiation Therapy in Renal Cell Carcinoma

Christensen M, Hannan R 2022 Oct 14

Enrichment of “Cribriform” morphologies (intraductal and cribriform adenocarcinoma) and genomic alterations in radiorecurrent prostate cancer

Shah RB, Palsgrove DN, Desai NB, Gagan J, Mennie A, Raj G, Hannan R 2022 Oct 35 1468-1474

Case Report: Adaptive radiotherapy in the radiation salvage of prostate cancer

Montalvo SK, Meng B, Lin MH, Park C, Desai NB, Hannan R, Garant A 2022 Aug 12

SABR for High-Risk Prostate Cancer: A Prospective Multilevel MRI-Based Dose Escalation Trial

Hannan R, Salamekh S, Desai NB, Garant A, Folkert MR, Costa DN, Mannala S, Ahn C, Mohamad O, Laine AM, Kim DW, Dickinson T, Raj GV, Shah RB, Wang J, Jia X, Choy H, Roehrborn CG, Lotan Y, Timmerman RD 2022 Jun 113 290-301

Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer

Hannan R, Dohopolski MJ, Pop LM, Mannala S, Watumull L, Womack KB, Gao A, Garant A, Arriaga YE, Bowman I, Chung J, Wang J, Ariizumi K, Ahn C, Timmerman R, Courtney K 2022 Jun 10

Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer

Hannan R, Christensen M, Hammers H, Christie A, Paulman B, Lin D, Garant A, Arafat W, Courtney K, Bowman I, Cole S, Sher D, Ahn C, Choy H, Timmerman R, Brugarolas J 2022 Apr 5 216-224

Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus

Freifeld Y, Pedrosa I, Mclaughlin M, Correa RM, Louie AV, Maldonado JA, Tang C, Kadow B, Kutikov A, Uzzo RG, Porta C, Bucknell NW, Siva S, Brugarolas J, Margulis V, Timmerman R, Hannan R 2022 Apr 40 166.e9-166.e13

Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer

Chen L, Gannavarapu BS, Desai NB, Folkert MR, Dohopolski M, Gao A, Ahn C, Cadeddu J, Bagrodia A, Woldu S, Raj GV, Roehrborn C, Lotan Y, Timmerman RD, Garant A, Hannan R 2022 Feb 12

Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma

Hannan R, Mohamad O, Diaz De Leon III A, Manna S, Pop LM, Zhang Z, Mannala S, Christie A, Christley S, Monson N, Ishihara D, Hsu EJ, Ahn C, Kapur P, Chen M, Arriaga YE, Courtney K, Cantarel B, Wakeland EK, Fu Y, Pedrosa I, Cowell L, Wang T, Margulis V, Choy H, Timmerman RD, Brugarolas J 2021 Dec 27 6716-6725

Metastasis-directed radiation therapy after radical cystectomy for bladder cancer

Miranda AF, Howard JM, McLaughlin M, Meng X, Clinton T, Şanli Ö, Garant A, Bagrodia A, Margulis V, Lotan Y, Hannan R, Desai N, Woldu SL 2021 Nov 39 790.e1-790.e7

PSA-Net: Deep learning–based physician style–aware segmentation network for postoperative prostate cancer clinical target volumes

Balagopal A, Morgan H, Dohopolski M, Timmerman R, Shan J, Heitjan DF, Liu W, Nguyen D, Hannan R, Garant A, Desai N, Jiang S 2021 Nov 121

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma

Schoenhals JE, Mohamad O, Christie A, Zhang Y, Li D, Singla N, Bowman I, Arafat W, Hammers H, Courtney K, Cole S, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Timmerman R, Brugarolas J, Hannan R 2021 Sep 6

A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer

Folkert MR, Zelefsky MJ, Hannan R, Desai NB, Lotan Y, Laine AM, Kim DW, Neufeld SH, Hornberger B, Kollmeier MA, McBride S, Ahn C, Roehrborn C, Timmerman RD 2021 Sep 111 101-109

Renal lipid metabolism abnormalities in obesity and clear cell renal cell carcinoma

Bobulescu IA, Pop LM, Mani C, Turner K, Rivera C, Khatoon S, Kairamkonda S, Hannan R, Palle K 2021 Sep 11

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade

Moore C, Hsu CC, Chen WM, Chen BP, Han C, Story M, Aguilera T, Pop LM, Hannan R, Fu YX, Saha D, Timmerman R 2021 Aug 110 1306-1316

A deep learning-based framework for segmenting invisible clinical target volumes with estimated uncertainties for post-operative prostate cancer radiotherapy

Balagopal A, Nguyen D, Morgan H, Weng Y, Dohopolski M, Lin MH, Barkousaraie AS, Gonzalez Y, Garant A, Desai N, Hannan R, Jiang S 2021 Aug 72

Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial

Margulis V, Freifeld Y, Pop LM, Manna S, Kapur P, Pedrosa I, Christie A, Mohamad O, Mannala S, Singla N, Wait M, Bagrodia A, Woldu SL, Gahan J, Brugarolas J, Timmerman R, Hannan R 2021 Jul 110 1135-1142

Type I IFN activating type I dendritic cells for antitumor immunity

Liang Y, Hannan R, Fu YX 2021 Jul 27 3818-3824

Hydrogel Spacer Rectal Wall Infiltration Associated With Severe Rectal Injury and Related Complications After Dose Intensified Prostate Cancer Stereotactic Ablative Radiation Therapy

McLaughlin MF, Folkert MR, Timmerman RD, Hannan R, Garant A, Hudak SJ, Costa DN, Desai NB 2021 Jul 6

Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC

All S, Garant A, Hannan R 2021 Jul 31 227-234

Long-Term Results of a Phase 1 Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Ablative Radiation Therapy for Liver Metastases

Folkert MR, Meyer JJ, Aguilera TA, Yokoo T, Sanford NN, Rule WG, Mansour J, Yopp A, Polanco P, Hannan R, Nedzi LA, Timmerman RD 2021 Apr 109 1387-1395

Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print]

Correa RJ, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L, Kaplan I, Mahadevan A, Chu W, Swaminath A, Hannan R, Onishi H, Teh BS, Muacevic A, Lo SS, Staehler M, Siva S 2021 Mar 7 404-405

Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder

Rouanne M, Bajorin DF, Hannan R, Galsky MD, Williams SB, Necchi A, Sharma P, Powles T 2020 Dec 3 728-738

Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer

Westover KD, Travis Mendel J, Dan T, Kumar K, Gao A, Pulipparacharuv S, Iyengar P, Nedzi L, Hannan R, Anderson J, Choe KS, Jiang W, Abdulrahman R, Rahimi A, Folkert M, Laine A, Presley C, Munro Cullum C, Choy H, Ahn C, Timmerman R 2020 Dec 22 1831-1839

Evolving Brachytherapy Boost in Prostate Cancer in the Era of Hypofractionation

Desai NB, Garant A, Hannan R, Folkert MR 2020 Nov 108 914-916

Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma

Patel V, Elias R, Formella J, Schwartzman W, Christie A, Cai Q, Malladi V, Kapur P, Vazquez M, McKay R, Pedrosa I, Hannan R, Hammers H, Brugarolas J 2020 Nov 8

The reintroduction of radiotherapy into the integrated management of kidney cancer

Dohopolski M, Hannan R, Wardak Z, Hammers H, Garant A 2020 Sep 26 448-459

Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity

Zhang F, Manna S, Pop LM, Chen ZJ, Fu YX, Hannan R 2020 Apr 30 129-138

Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes

Lu T, Wang S, Xu L, Zhou Q, Singla N, Gao J, Manna S, Pop L, Xie Z, Chen M, Luke JJ, Brugarolas J, Hannan R, Wang T 2020 Feb 5

Addition of Iodinated Contrast to Rectal Hydrogel Spacer to Facilitate MRI-Independent Target Delineation and Treatment Planning for Prostate Cancer

Atluri PS, Gannavarapu BS, Timmerman RD, Garant A, Hannan R, Folkert MR, Desai NB 2019 Nov 9 e528-e533

The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Correa RJ, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L, Kaplan I, Mahadevan A, Chu W, Swaminath A, Hannan R, Onishi H, Teh BS, Muacevic A, Lo SS, Staehler M, Siva S 2019 Nov 5 958-969

Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer

Zhang Y, Schoenhals J, Christie A, Mohamad O, Wang C, Bowman I, Singla N, Hammers H, Courtney K, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Timmerman R, Brugarolas J, Hannan R 2019 Oct 105 367-375

PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response

Vento J, Mulgaonkar A, Woolford L, Nham K, Christie A, Bagrodia A, De Leon AD, Hannan R, Bowman I, McKay RM, Kapur P, Hao G, Sun X, Brugarolas J 2019 Jun 7

Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma

Wardak Z, Christie A, Bowman A, Stojadinovic S, Nedzi LA, Barnett SL, Patel TR, Mickey BE, Whitworth LA, Hannan R, Brugarolas JB, Timmerman R 2019 Apr 17 e273-e280

Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases

Bowman IA, Bent A, Le T, Christie A, Wardak Z, Arriaga Y, Courtney K, Hammers H, Barnett S, Mickey B, Patel T, Whitworth T, Stojadinovic S, Hannan R, Nedzi L, Timmerman R, Brugarolas J 2019 Apr 17 e263-e272

Stereotactic body radiation therapy for renal cell carcinoma with inferior vena cava thrombus-initial experience report and literature review

Freifeld Y, Margulis V, Woldu SL, Timmerman R, Brugarolas J, Hannan R 2019 3 71-77

Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: The randomized phase III NRG Oncology RTOG 0521 Trial

Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM 2019 37 1159-1168

Fully automated organ segmentation in male pelvic CT images

Balagopal A, Kazemifar S, Nguyen D, Lin MH, Hannan R, Owrangi A, Jiang S 2018 Dec 63

Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study

Woldu SL, Matulay JT, Clinton TN, Singla N, Freifeld Y, Sanli OM, Krabbe LM, Hutchinson RC, Lotan Y, Hammers H, Hannan R, Brugarolas JB, Bagrodia A, Margulis V 2018 Dec 16 e1221-e1235

Reliable gene mutation prediction in clear cell renal cell carcinoma through multi-classifier multi-objective radiogenomics model

Chen X, Zhou Z, Hannan R, Thomas K, Pedrosa I, Kapur P, Brugarolas J, Mou X, Wang J 2018 Oct 63

An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors

Wang T, Lu R, Kapur P, Jaiswal BS, Hannan R, Zhang Z, Pedrosa I, Luke JJ, Zhang H, Goldstein LD, Yousuf Q, Gu YF, McKenzie T, Joyce A, Kim MS, Wang X, Luo D, Onabolu O, Stevens C, Xie Z, Chen M, Filatenkov A, Torrealba J, Luo X, Guo W, He J, Stawiski E, Modrusan Z, Durinck S, Seshagiri S, Brugarolas J 2018 Sep 8 1142-1155

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer–specific Mortality: Competition Between Age and Time to Biochemical Failure

Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JW, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, Spratt DE 2018 Sep 1 276-282

Segmentation of the prostate and organs at risk in male pelvic CT images using deep learning

Kazemifar S, Balagopal A, Nguyen D, McGuire S, Hannan R, Jiang S, Owrangi A 2018 Jul 4

Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy

Mohamad O, Diaz de Leon A, Schroeder S, Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB, Laine A, Albuquerque K, Iyengar P, Arriaga Y, Courtney K, Gerber DE, Hammers H, Choy H, Timmerman R, Brugarolas J, Hannan R 2018 Jul 7

Natural history of ‘second’ biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study

Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney KD, Bagrodia A, Gahan J, Zumsteg ZS, Folkert MR, Laine AM, Hannan R, Spratt DE, Desai NB 2018 Mar 121 365-372

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Dong H, Peng H, Fu YX 2018 Feb 128 580-588

Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study

Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng FY, Spratt DE 2017 Sep 120 351-357

A new method to reconstruct intra-fractional prostate motion in volumetric modulated arc therapy

Chi Y, Rezaeian NH, Shen C, Zhou Y, Lu W, Yang M, Hannan R, Jia X 2017 Jun 62 5509-5530

Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases

Wang CJ, Christie A, Lin M, Jung M, Weix D, Huelsmann L, Kuhn K, Meyer JJ, Desai NB, Kim DW, Pedrosa I, Margulis V, Cadeddu JA, Sagalowsky AI, Gahan J, Laine AM, Xie X, Choy H, Brugarolas JB, Timmerman R, Hannan R 2017 May 98 91-100

Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials

Jones RT, Hassan Rezaeian N, Desai NB, Lotan Y, Jia X, Hannan R, Kim DW, Hornberger B, Dubas J, Laine AM, Zelefsky MJ, Timmerman R, Folkert MR 2017 Feb 42 341-347

Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment

Ishihara D, Pop L, Takeshima T, Iyengar P, Hannan R 2016 Oct 1-18

Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF

Takeshima T, Pop LM, Laine A, Iyengar P, Vitetta ES, Hannan R 2016 Oct 113 11300-11305

Stereotactic body radiation therapy for low and intermediate risk prostate cancer - Results from a multi-institutional clinical trial

Hannan R, Tumati V, Xie X, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim DW, Pistenmaa D, Lotan Y, Timmerman R 2016 May 59 142-151

A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases

Meyer JJ, Foster RD, Lev-Cohain N, Yokoo T, Dong Y, Schwarz RE, Rule W, Tian J, Xie Y, Hannan R, Nedzi L, Solberg T, Timmerman R 2016 Jan 23 218-224

Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy

Jacobs C, Tumati V, Kapur P, Yan J, Xie XJ, Hannan R, Hsieh JT, Kim DW, Saha D 2015 Dec 4 1844-1852

Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma

Huelsmann L, Kim DN, Hannan R, Watumull LM, Brugarolas J 2015 Aug 13 e321-e323

Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus

Hannan R, Margulis V, Chun SG, Cannon N, Kim DW, Abdulrahman RE, Sagalowsky AI, Pedrosa I, Choy H, Brugarolas JB, Timmerman R 2015 Jan 16 657-661

Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure

Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R, Kalnicki S, Guha C, Garg MK 2014 Nov 4 409-414

Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy

Jacobs CD, Chun SG, Yan J, Xie X, Pistenmaa DA, Hannan R, Lotan Y, Roehrborn C, Choe KS, Kim DW 2014 Jun 15 699-706

Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer

Hannan R, Zhang H, Wallecha A, Singh R, Liu L, Cohen P, Alfieri A, Rothman J, Guha C 2012 Dec 61 2227-2238

Hypofractionated whole-breast radiation therapy: Does breast size matter?

Hannan R, Thompson RF, Chen Y, Bernstein K, Kabarriti R, Skinner W, Chen CC, Landau E, Miller E, Spierer M, Hong L, Kalnicki S 2012 Nov 84 894-901

Timing of postseed imaging influences rectal dose-volume parameters for cesium-131 prostate seed implants

Yaparpalvi R, Hannan R, Landau E, Kahan N, Bodner W, Kuo HC, Minsky L, Mehta KJ, Garg MK, Kalnicki S, Guha C 2012 Nov 11 489-494

The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells

Bowne WB, Sookraj KA, Vishnevetsky M, Adler V, Sarafraz-Yazdi E, Lou S, Koenke J, Shteyler V, Ikram K, Harding M, Bluth MH, Ng M, Brandt-Rauf PW, Hannan R, Bradu S, Zenilman ME, Michl J, Pincus MR 2008 Dec 15 3588-3600

PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo

Michl J, Scharf B, Schmidt A, Huynh C, Hannan R, Von Gizycki H, Friedman FK, Brandt-Rauf P, Fine RL, Pincus MR 2006 Oct 119 1577-1585